Lumida
/ADCT
⌘K
ADC Therapeutics SA

ADC Therapeutics SA

ADCT
$0.97USD-3.16%-0.03 today

MARKET CAP

123.2M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$5

AI Summary

Stalk
Buy NowMedium

ADCT has formed an early post-capitulation base in Stage 1 with clear exhaustion after a deep washout. The chart is extreme oversold, and RSI is recovering from lows. Price is tightly holding above the rising 9EMA and 21EMA, confirming support. Mean‐reversion rules in Stage 1 mandate a medium‐term bullish bias and open a buy‐now opportunity at short‐term EMA support.

  • Q1 net product revenues rose 15% YoY to $20M, indicating stable demand for Zynlanta.
  • $231M cash runway supports trials and operations through 2028, reducing dilution risk.
  • Q1 net loss narrowed to $33M vs $38.6M YoY but still indicates negative profitability.
Full analysis →
Insider Trades22 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 13, 2026BuyADCTLisa Michelle KalleboChief Accounting Officer68,333$3.99$123.2M-80.62%+23.79%$272.6K+28.11%Buy Now
Feb 13, 2026BuyADCTJose CarmonaChief Financial Officer297,480$3.99$123.2M-80.62%+23.79%$1.2M+19.67%Buy Now
Feb 13, 2026BuyADCTMohamed ZakiChief Medical Officer309,803$3.99$123.2M-80.62%+23.79%$1.2M+23.09%Buy Now
Feb 13, 2026BuyADCTPeter J GrahamChief Legal Officer328,094$3.99$123.2M-80.62%+23.79%$1.3M+25.82%Buy Now
Feb 13, 2026BuyADCTAmeet MallikChief Executive Officer1,003,231$3.99$123.2M-80.62%+23.79%$4.0M+36.22%Buy Now
Dec 6, 2025SellADCTLisa Michelle KalleboChief Accounting Officer7,140$3.29$123.2M-80.62%+23.79%$23.5K-9.17%Buy Now
Dec 6, 2025SellADCTMohamed ZakiChief Medical Officer41,068$3.29$123.2M-80.62%+23.79%$135.1K-8.87%Buy Now
Dec 6, 2025SellADCTPeter J GrahamChief Legal Officer49,508$3.29$123.2M-80.62%+23.79%$162.9K-12.12%Buy Now
Dec 6, 2025SellADCTJose CarmonaChief Financial Officer53,236$3.29$123.2M-80.62%+23.79%$175.1K-9.82%Buy Now
Dec 6, 2025SellADCTAmeet MallikChief Executive Officer233,146$3.29$123.2M-80.62%+23.79%$767.1K-15.02%Buy Now
May 6, 2025SellADCTAmeet MallikChief Executive Officer26,758$1.29$123.2M-80.62%+23.79%$34.5K-1.69%Buy Now
Feb 13, 2025BuyADCTLisa Michelle KalleboChief Accounting Officer41,900$1.61$123.2M-80.62%+23.79%$67.5K+116.40%Buy Now
Feb 13, 2025BuyADCTPeter J GrahamChief Legal Officer220,000$1.61$123.2M-80.62%+23.79%$354.2K+116.68%Buy Now
Feb 13, 2025BuyADCTMohamed ZakiChief Medical Officer230,000$1.61$123.2M-80.62%+23.79%$370.3K+98.76%Buy Now
Feb 13, 2025BuyADCTJose CarmonaChief Financial Officer240,000$1.61$123.2M-80.62%+23.79%$386.4K+79.50%Buy Now
Feb 13, 2025BuyADCTAmeet MallikChief Executive Officer650,000$1.61$123.2M-80.62%+23.79%$1.0M+69.97%Buy Now
Dec 6, 2024SellADCTLisa Michelle KalleboChief Accounting Officer6,503$3.13$123.2M-80.62%+23.79%$20.4K-15.30%Buy Now
Dec 6, 2024SellADCTMohamed ZakiChief Medical Officer37,112$3.13$123.2M-80.62%+23.79%$116.2K-13.75%Buy Now
Dec 6, 2024SellADCTPeter J GrahamChief Legal Officer41,458$3.13$123.2M-80.62%+23.79%$129.8K-18.03%Buy Now
Dec 6, 2024SellADCTJose CarmonaChief Financial Officer48,108$3.13$123.2M-80.62%+23.79%$150.6K-13.75%Buy Now
Dec 6, 2024SellADCTAmeet MallikChief Executive Officer238,343$3.13$123.2M-80.62%+23.79%$746.0K-20.42%Buy Now
May 7, 2024SellADCTAmeet MallikChief Executive Officer29,731$4.48$123.2M-80.62%+23.79%$133.2K-2.48%Buy Now